A Phase 1 interventional study of JNJ-87562761 in Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Janssen Research & Development, LLC · Phase 1, Interventional, and Treatment
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D[s]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.
This study's enrollment of 17 is below the median of 50 across 3,374 interventional studies indexed under Recurrence.
Browse Recurrence studies →Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.
Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive JNJ-87562761 during the Part 1 (Dose escalation) to determine the recommended phase 2 dose (RP2D) regimen(s). The dose will be escalated sequentially until the RP2D regimen(s) have been identified. In Part 2 (Dose expansion) participants will receive JNJ-87562761 at the RP2D regimen(s) determined in Part 1.
Drug: JNJ-87562761
JNJ-87562761 will be administered.
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity.
Time frame: up to approximately 3 years
Part 1 and 2: Number of Participants with Adverse Events (AEs)
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Time frame: up to approximately 3 years
Part 2: Number of Participants with Clinically Significant Abnormal Laboratory Values
Number of participants with clinically significant abnormal laboratory values (hematology or chemistry) will be reported.
Time frame: up to approximately 3 years
Serum Concentration of JNJ-87562761
Serum samples will be analyzed to determine concentrations of JNJ-87562761.
Time frame: up to approximately 3 years
Pharmacokinetic (PK) Parameters of JNJ-87562761
PK parameters for JNJ-87562761 will be evaluated.
Time frame: up to approximately 3 years
Number of Participants with Presence of Anti-JNJ-87562761 Antibodies
Number of participants with presence of anti-JNJ-87562761 antibodies will be reported.
Time frame: up to approximately 3 years
Percentage of Participants with Response
Overall response is defined as a best response of partial response (PR) or better as assessed according to the International Myeloma Working Group (IMWG) 2016 response criteria.
Time frame: up to approximately 3 years
Percentage of Participants Who Achieve Very Good Partial Response (VGPR) or Better
VGPR or better response is defined as the percentage of participants who achieve a best response of VGPR or better as assessed by IMWG 2016 response criteria.
Time frame: up to approximately 3 years
Percentage of Participants Who Achieve Complete Response (CR) or Better
CR or better response is defined as percentage of participants who achieve a best response of CR or better as assessed by IMWG 2016 response criteria.
Time frame: up to approximately 3 years
Percentage of Participants Who Achieve Stringent Complete Response (sCR)
sCR is defined as the percentage of participants who achieve a best response of sCR as assessed by IMWG 2016 response criteria.
Time frame: up to approximately 3 years
Duration of Response (DOR)
DOR is defined for participants who achieve a response of PR or better as the time from the first efficacy evaluation at which the participant met all criteria for a response of PR or better to the time of first documented evidence of progressive disease or death, assessed by IMWG 2016 response criteria.
Time frame: up to approximately 3 years
Time to Response (TTR)
TTR is defined for participants who achieve a response of PR or better as the time from the first dose of study drug to the time of the first efficacy evaluation at which the participant met all criteria for a response of PR or better, assessed by IMWG 2016 response criteria.
Time frame: up to approximately 3 years
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC